RR

Robert Rob Merriel

Mr Merriel is has over 35 years of experience working in medical research (Hudson Institute of Medical Research and Baker Institute), public healthcare services (Melbourne Health and Southern Health) and commercial organisations (Pacific Dunlop and Deloitte Consulting). He has been a Director of two Venture Capital Funds and a Director and Company Secretary of several biotechnology focused medical research institute spin-off companies. Mr Merriel was appointed as the Chief Financial Officer, Chief Commercialisation Officer and Company Secretary of the Hudson Institute of Medical Research in May 2014, positions he continues to hold today. He is member of Risk Committee.

Holding

Company
Last Notice
Direct Shares
Indirect Shares
Options
Convertibles
18/01/244,440,125N/A20,443,211N/A

Transactions

Company
Date
Type
Amount
Price
Value
Notes
18/01/24
Exercise
2,900,000$0.005$13,050Exercise of options
18/01/24
Buy
2,900,000$0.005$13,050Exercise of options
01/05/23
Buy
1,540,125$0.007$10,780Exercise of options
01/05/23
Exercise
1,540,125$0.007$10,780Exercise of options
12/09/22
Issued
1,240,726$0.013$16,129Director remuneration